Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 12/20 | 0.48 |
| ▸ | PGR | P06401 | 2/20 | 0.41 |
| ▸ | GCGR | P47871 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 3/20 | 0.35 |
| ▸ | MMP9 | P14780 | 3/20 | 0.35 |
| ▸ | MMP8 | P22894 | 2/20 | 0.35 |
| ▸ | MMP13 | P45452 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26050391 | 0.95 | PDK2 (0.44) | PDK2PGRGCGRMAPK14MMP2 | |
| SCHEMBL26050352 | 0.95 | PDK2 (0.44) | PDK2PGRGCGRMAPK14MMP2 | |
| SCHEMBL20927687 | 0.95 | PDK2 (0.44) | PDK2PGRGCGRMAPK14MMP2 | |
| SCHEMBL22989719 | 0.95 | PDK2 (0.44) | PDK2PGRGCGRMAPK14MMP2 | |
| SCHEMBL26050398 | 0.95 | PDK2 (0.44) | PDK2PGRGCGRMAPK14MMP2 | |
| SCHEMBL21037521 | 0.95 | PDK2 (0.44) | PDK2PGRGCGRMAPK14MMP2 | |
| SCHEMBL24257883 | 0.95 | PDK2 (0.44) | PDK2PGRGCGRMAPK14MMP2 | |
| SCHEMBL24257897 | 0.95 | PDK2 (0.44) | PDK2PGRGCGRMAPK14MMP2 | |
| SCHEMBL26050392 | 0.93 | PDK2 (0.43) | PDK2PGRGCGRMAPK14MMP2 | |
| SCHEMBL1994589 | 0.92 | PDK2 (0.41) | PDK2MMP2MMP9MMP8MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271989-A1 | METAL COMPLEXES | UDC IRELAND LIMITED (IE) | 2023-08-31 | — | — | US | disclosed |
| US-20230271989-A1 | METAL COMPLEXES | UDC IRELAND LIMITED (IE) | 2023-08-31 | — | — | US | disclosed |
| WO-2022034046-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271989-A1 | METAL COMPLEXES | AP3M1, AP1M1, AP2M1 | PDK2 1385/4885PGR 2872/4885GCGR 4761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.